Eli Lilly to Buy Cancer Drug Specialists Loxo Oncology
In the second major pharmaceutical deal of the year, Eli Lilly will pay about $8 billion for Loxo Oncology.
Lilly’s Elanco Expects IPO to Raise $1.4B
The animal health spinoff is the second major industry player to go public, following Zoetis' successful offering.
Eli Lilly to Spin Off Animal-Health Business
Eli Lilly reported a quarterly loss of $260 million and announced plans for an IPO of Elanco by the end of 2018.
CFOs on the Move: Week Ending Oct. 6
Eli Lilly, Mattel, Georgia Power, Pier 1 Imports, Bravo Brio Restaurant Group, Purchasing Power,, White Energy
Lilly Veteran Josh Smiley Promoted to CFO
Smiley takes over from Derica Rice amid a cost-cutting push aimed at freeing up cash for Lilly to invest in developing new drugs.
Eli Lilly to Trim 3,500 Jobs to Save $500 Million
The drugmaker is seeking to become "a leaner, more nimble global organization" as it invests in a new generation of medicines.
CFOs on the Move: Week Ending June 3
Uber, Eli Lilly, Occidental Petroleum, Dunkin' Brands, Cloudflare, American Express Business Travel, Neiman Marcus, Proterra, Knoll, Tivity Health
New Products Fuel Eli Lilly Q1 Earnings Beat
Drugs such as the diabetes treatment Trulicity "led the company to a strong quarter of volume-driven revenue growth."
Lilly Buys Vetmedica Pet Vaccines for $885M
The deal will diversify Lilly's Elanco animal medicine business, adding vaccines for rabies and other feline and canine illnesses.